Research · Sep 3, 2026
[C] Citigroup Thesis 2026: Fraser Transformation + Banamex IPO Test ROTCE Recovery From 8% Toward 11-12%
Citigroup FY2025 revenue ~$81B (+3-5%) with net income ~$13.5B and adj. EPS ~$7.00 — recovering from FY2023 EPS trough $4.04 reflecting transformation costs + cyclical pressures. ROTCE ~8% remains substantially below targeted 11-12% and below peer megabank ROTCE of 13-17% (JPMorgan/Bank of America). FY2024 corporate restructuring eliminated multi-decade segment confusion replacing legacy ICG/PB/WM/LF structure with new 5-segment structure: Services + Markets + Banking + US Personal Banking + Wealth. Strategic transformation milestones: 13 international consumer banking franchise exits announced 2021, Asia consumer divested 2022-2023, Russia exit, Banamex Mexico IPO planned (~$4-7B proceeds expected, FY2025-2026 execution). CET1 ratio 13.7%; capital return $5-6B/year constrained by elevated SCB stress capital buffer 4.1%. FY2026 thesis: Banamex IPO + transformation + ROTCE recovery toward 10% by FY2027; key risks: regulatory consent orders extend, ROTCE recovery slower than projected, capital markets weakness extends.